Results 211 to 220 of about 513,228 (356)
Abstract Background Schwann cells provide peripheral nerve trophic support, myelinate axons, and assist in repair. However, Schwann cell repair capacity is limited by chronic injury, disease, and aging. Schwann cell reprogramming is a cellular conversion strategy that could provide a renewable cell supply to repair injured nerves.
Lauren Belfiore +7 more
wiley +1 more source
Peripheral Neuropathy Associated With Proteasome Inhibitors and Immunomodulatory Drugs: A Pharmacovigilance Disproportionality Analysis Using VigiBase. [PDF]
Braga LP +8 more
europepmc +1 more source
Relations between auditory brainstem response and threshold metrics in normal and impaired hearing listeners [PDF]
Ernst, Frauke +3 more
core +1 more source
Abstract Neural crest cells are a transient cell population that emerges from the dorsal neural tube during neurulation and migrates extensively throughout the embryo. Among their diverse derivatives, glial cells (such as Schwann and satellite ganglionic cells) and melanocytes represent two major lineages. In vitro studies suggested they share a common
Chaya Kalcheim
wiley +1 more source
Common Peroneal Nerve Entrapment Neuropathy Involving a Vein-Case Report. [PDF]
Yoshinaga T +6 more
europepmc +1 more source
Variability of resting endoscopic grading for assessment of recurrent laryngeal neuropathy in horses [PDF]
Justin Perkins +5 more
openalex +1 more source
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia +2 more
wiley +1 more source
Adverse Drug Reaction to Linezolid in Drug-Resistant Tuberculosis: A Systematic Review. [PDF]
Oktaviani E, Anggadiredja K, Amalia L.
europepmc +1 more source
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons +17 more
wiley +1 more source
Pharmacovigilance study on neurological adverse reactions of proteasome inhibitors in the FDA adverse event reporting system. [PDF]
Li S, Ling T, Liu Y, Li J.
europepmc +1 more source

